- About Us
- Advertise
- Contact Us
- CureToday.com
- CancerNetwork.com
- OncLive.com
- Do Not Sell My Information
- Privacy
- Terms & Conditions
© 2021 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
DLBCL | Clinical
Tafasitamab/Lenalidomide Combo Demonstrates Favorable Efficacy in DLBCL
July 21, 2021
In the case that a clinical trial is not an option for a 75-year-old male patient with diffuse large B-cell lymphoma who is ineligible for transplant due to older age and high risk. Herbert A. Eradat, MD, explains his treatment plan.
Tafasitamab Plus Lenalidomide Shows Manageable Safety Profile in R/R DLBCL
July 15, 2021
Gilles Salles, MD, the lymphoma service chief at Memorial Sloan Kettering Cancer Center discusses the safety profile of tafasitamab combined with lenalidomide for the treatment of relapsed or refractory diffuse large B-cell lymphoma, based on results of the L-MIND trial.
Roundtable Discussion: Gordon Explores Second-line Transplant and CAR T-Cell Therapy for DLBCL
July 07, 2021
During a Targeted Oncology Case-Based Roundtable events, Leo I. Gordon, MD, led a discussion about second-line treatment of diffuse large B-cell lymphoma.
ZUMA-7 Meets Primary Endpoint and Key Secondary Endpoint in R/R LBCL
June 28, 2021
A primary analysis of the phase 3 ZUMA-7 study shows the benefits of axicabtagene ciloleucel for patients with relapsed or refractory large B-cell lymphoma in the second and third-line settings.
Novel Tafasitamab Combination Finds a Role in Second-line DLBCL Treatment
June 22, 2021
During a Targeted Oncology Case-Based Roundtable event, Jakub Svoboda, MD, discussed the case of a 75-year-old patient with diffuse large b-cell lymphoma.
Phase 3 Front-MIND Trial Initiated to Explore Tafasitamab Triplet in DLBCL
June 16, 2021
A phase 3 trial has been initiated to explore the potential of a triplet regimen of tafasitamab-cxix, lenalidomide, and R-CHOP as a treatment options for patients with newly diagnosed diffuse large B-cell lymphoma.
Real World Data Show Patients with DLBCL Receive Axi-Cel/Tisa-Cel Prior to Treatment Failure
June 13, 2021
Real world data looking at the use of the recently approved CAR T-cell therapies tisagenlecleucel and axicabtagene ciloleucel show that patients are receiving it prior to failing treatments and that 1 in 6 patients were experiencing relapse after treatment.
Naratuximab Emtansine With Rituximab Leads to Durable Responses in R/R DLBCL
June 12, 2021
Naratuximab emtansine in combination with rituximab showed deep responses and a duration of response that was not reached in patients with relapsed or refractory diffuse large B-cell lymphoma, according to findings from a phase 2 trial presented during the EHA 2021 Virtual Congress.
Durable Responses Seen With Tafasitamab/Lenalidomide Combo in DLBCL
June 06, 2021
The combination of tafasitamab-cxix and lenalidomide in patients with relapsed/refractory diffuse large B-cell lymphoma showed sustainable responses at 3-year follow-up of the phase 2 L-MIND trial.
Polatuzumab With Rituximab and Lenalidomide Shown Safe and Effective for Relapsed/Refractory DLBCL
June 05, 2021
In patients with relapsed/refractory diffuse large B-cell lymphoma treated with the triplet combinaton of polatuzumab vedotin, rituximab and lenalidomide, therapy was considered to be safe and effective.